Journal of Pediatric Hematology/Oncology最新文献

筛选
英文 中文
Pyrites: A Rectal Mass. 黄铁矿直肠肿块
IF 0.9 4区 医学
Journal of Pediatric Hematology/Oncology Pub Date : 2024-11-01 Epub Date: 2024-07-19 DOI: 10.1097/MPH.0000000000002900
Sam Lyvannak, Bun Sereyleak, Mariko Kakazu, Hor Bisiphan, Jason Jarzembowski, Bruce Camitta
{"title":"Pyrites: A Rectal Mass.","authors":"Sam Lyvannak, Bun Sereyleak, Mariko Kakazu, Hor Bisiphan, Jason Jarzembowski, Bruce Camitta","doi":"10.1097/MPH.0000000000002900","DOIUrl":"10.1097/MPH.0000000000002900","url":null,"abstract":"","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"446-447"},"PeriodicalIF":0.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eosinophilia in a Neonate With Trisomy 21, Transient Abnormal Myelopoiesis, and Neurofibromatosis Type 1. 患有 21 三体综合征、一过性骨髓造血异常和神经纤维瘤病 1 型的新生儿嗜酸性粒细胞增多症
IF 0.9 4区 医学
Journal of Pediatric Hematology/Oncology Pub Date : 2024-11-01 Epub Date: 2024-09-18 DOI: 10.1097/MPH.0000000000002950
Kayla M Schmittau, Brian M Walker, Nupur Mittal, Lisa Giordano
{"title":"Eosinophilia in a Neonate With Trisomy 21, Transient Abnormal Myelopoiesis, and Neurofibromatosis Type 1.","authors":"Kayla M Schmittau, Brian M Walker, Nupur Mittal, Lisa Giordano","doi":"10.1097/MPH.0000000000002950","DOIUrl":"10.1097/MPH.0000000000002950","url":null,"abstract":"<p><p>Transient abnormal myelopoiesis is a syndrome that causes excess proliferation of immature myeloid cells and occurs in 10% to 15% of neonates with trisomy 21. Transient abnormal myelopoiesis usually resolves spontaneously but occasionally requires treatment with chemotherapy. The disorder is not typically associated with eosinophilia. We report on a neonate with trisomy 21 and transient abnormal myelopoiesis characterized by leukocytosis with marked eosinophilia. The patient required 2 cycles of cytarabine for adequate myeloproliferative control. Furthermore, this patient was subsequently also diagnosed with neurofibromatosis type 1, which has no known association with trisomy 21 or transient abnormal myelopoiesis.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"419-423"},"PeriodicalIF":0.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding Diagnosis Delay in Children With Cancer: Evidence From a Single Institution in Jordan. 了解癌症儿童的诊断延迟:来自约旦单一机构的证据。
IF 0.9 4区 医学
Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-12 DOI: 10.1097/MPH.0000000000002926
Anwar Al-Nassan, Tariq Almanaseer, Saja Malkawi, Farah Al-Bitar, Dayana Jibrin, Omaima El-Qurnah, Shaima Bataineh, Maen Kamal, Salsabeel Sweidan, Mayada Abu-Shanab, Iyad Sultan
{"title":"Understanding Diagnosis Delay in Children With Cancer: Evidence From a Single Institution in Jordan.","authors":"Anwar Al-Nassan, Tariq Almanaseer, Saja Malkawi, Farah Al-Bitar, Dayana Jibrin, Omaima El-Qurnah, Shaima Bataineh, Maen Kamal, Salsabeel Sweidan, Mayada Abu-Shanab, Iyad Sultan","doi":"10.1097/MPH.0000000000002926","DOIUrl":"10.1097/MPH.0000000000002926","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the factors associated with diagnosis delay in children with cancer who are treated at a single institution, which caters to most children with cancer in Jordan.</p><p><strong>Methods: </strong>This was a cross-sectional study with a retrospective chart review of selected patients who were diagnosed from August 2018 to December 2021. Data on patient and household characteristics, medical history, and diagnostic delay were collected through structured interviews. Univariable and multivariable linear and logistic regression models were used to identify predictors of delay.</p><p><strong>Results: </strong>The study included a cohort of 202 patient-caregiver pairs, with a median total delay from symptom onset to treatment initiation of 47 days (interquartile range [IQR], 21 to 114 d). Notably, 86% of families pursued medical consultation within a month of recognizing symptoms. A regression model revealed CNS tumors as a significant independent predictor of increased total delay ( P =0.002), with affected patients experiencing a median delay markedly longer than those with other cancer types. In addition, older patient age predicted longer total delay ( P =0.025). Symptomatology played a pivotal role in the timeliness of the diagnosis; specifically, visible symptoms such as pallor, bruises, and jaundice were associated with more expedient medical attention, with significantly shorter delays ( P values: 0.011, <0.001, and 0.045, respectively). Furthermore, our investigation disclosed a notable variance in symptom prevalence across different cancer categories, elucidating the complex relationship between clinical presentation and diagnostic timelines.</p><p><strong>Conclusions: </strong>This study highlights the importance of the diagnosis of CNS tumors, patient age, and symptoms in predicting diagnosis delay in pediatric oncology patients. These findings can inform interventions to reduce delays in diagnosis and improve outcomes for these patients. These insights are crucial for developing targeted educational programs aimed at healthcare professionals and families to accelerate the recognition and referral of pediatric cancer cases.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e508-e514"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Omalizumab for Treatment of Anti-GD2 Antibody-related Urticaria. 奥马珠单抗治疗抗GD2抗体相关性荨麻疹。
IF 0.9 4区 医学
Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-22 DOI: 10.1097/MPH.0000000000002939
Rachel Glincher, Angela Lentini-Rivera, Latisha Andre Jones, Linda D'Andrea, Christina Durney, Christine Kasper, Yichih Lin, Leslie Shrager, Alina Markova, Mario Lacouture, Shakeel Modak
{"title":"Omalizumab for Treatment of Anti-GD2 Antibody-related Urticaria.","authors":"Rachel Glincher, Angela Lentini-Rivera, Latisha Andre Jones, Linda D'Andrea, Christina Durney, Christine Kasper, Yichih Lin, Leslie Shrager, Alina Markova, Mario Lacouture, Shakeel Modak","doi":"10.1097/MPH.0000000000002939","DOIUrl":"10.1097/MPH.0000000000002939","url":null,"abstract":"<p><p>Outcomes for high-risk neuroblastoma have improved with the addition of antidisialoganglioside (GD2) antibody-mediated immunotherapy to multimodality therapy. Urticaria is an expected side effect of anti-GD2 immunotherapy. Rarely, despite maximal use of antihistamines and H2 receptor antagonists, refractory urticaria can result in impaired quality of life, and delays or discontinuation of immunotherapy. The anti-IgE monoclonal antibody, omalizumab, is approved for the treatment of asthma and chronic spontaneous urticaria. We successfully managed grade 3, naxitamab-related urticaria refractory to standard management in 2 patients using omalizumab, allowing for continued anti-GD2 immunotherapy. Omalizumab did not impact antitumor activity or immunogenicity of naxitamab.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e531-e533"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allogeneic Hematopoietic Cell Transplantation With Reduced Toxicity Conditioning for Pediatric B Lymphoid Malignancy. 针对小儿B淋巴细胞恶性肿瘤的异体造血细胞移植与减毒调理。
IF 0.9 4区 医学
Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-12 DOI: 10.1097/MPH.0000000000002936
Yuki Naito, Shinya Osone, Kohei Mitsuno, Takuyo Kanayama, Azusa Mayumi, Toshihiko Imamura, Tomoko Iehara
{"title":"Allogeneic Hematopoietic Cell Transplantation With Reduced Toxicity Conditioning for Pediatric B Lymphoid Malignancy.","authors":"Yuki Naito, Shinya Osone, Kohei Mitsuno, Takuyo Kanayama, Azusa Mayumi, Toshihiko Imamura, Tomoko Iehara","doi":"10.1097/MPH.0000000000002936","DOIUrl":"10.1097/MPH.0000000000002936","url":null,"abstract":"<p><strong>Background: </strong>Conventional conditioning regimens for children with lymphoid malignancy undergoing allogeneic hematopoietic cell transplantation (HCT) are myeloablative and involve high-dose total body irradiation (TBI). Such regimens are associated with significant late complications.</p><p><strong>Observations: </strong>Here, we used a reduced-toxicity conditioning regimen comprising fludarabine, cytarabine, melphalan, and low-dose TBI (FLAMEL) to treat 5 patients with lymphoid malignancy before HCT. Four patients maintained complete remission (range, 18 to 63 mo), whereas the remaining patient who had positive minimal residual disease (MRD) before HCT relapsed.</p><p><strong>Conclusions: </strong>FLAMEL might be a suitable conditioning regimen for children with lymphoid malignancy if pre-HCT MRD is negative.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e537-e540"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Haploidentical Stem Cell Transplants in Children With Sickle Cell Disease: A Single Center Real-world Experience. 镰状细胞病患儿的单倍体干细胞移植:单中心真实体验
IF 0.9 4区 医学
Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-26 DOI: 10.1097/MPH.0000000000002946
Samer Abdelkader, Rikin Shah, David Crawford, Ashley Baker, Anand Srinivasan
{"title":"Haploidentical Stem Cell Transplants in Children With Sickle Cell Disease: A Single Center Real-world Experience.","authors":"Samer Abdelkader, Rikin Shah, David Crawford, Ashley Baker, Anand Srinivasan","doi":"10.1097/MPH.0000000000002946","DOIUrl":"10.1097/MPH.0000000000002946","url":null,"abstract":"","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e556-e557"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
XMEN-associated Systemic EBV-positive T-cell Lymphoma of Childhood: Report of Two Cases and Literature Review. 与 XMEN 相关的儿童系统性 EBV 阳性 T 细胞淋巴瘤:两例病例报告和文献综述。
IF 0.9 4区 医学
Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-27 DOI: 10.1097/MPH.0000000000002940
Ping Cao, Xiao Zhang, Yang Fu, Hongsheng Wang, Yi Yu, Xiaohua Zhu, Junye Jiang, Xiaowen Zhai
{"title":"XMEN-associated Systemic EBV-positive T-cell Lymphoma of Childhood: Report of Two Cases and Literature Review.","authors":"Ping Cao, Xiao Zhang, Yang Fu, Hongsheng Wang, Yi Yu, Xiaohua Zhu, Junye Jiang, Xiaowen Zhai","doi":"10.1097/MPH.0000000000002940","DOIUrl":"10.1097/MPH.0000000000002940","url":null,"abstract":"<p><p>X-linked immunodeficiency with magnesium defect, Epstein-Barr virus (EBV) infection, and neoplasia (XMEN) is an extremely rare inborn error of immunity (IEI) caused by X-linked recessive inheritance and loss-of-function mutations in the MAGT1 gene, resulting in magnesium ion channel defects. This article reports 2 cases of systemic EBV-positive T-cell Lymphoma of childhood (SETLC) associated with XMEN, which have not been reported before. Whole exome sequencing (WES) in their family revealed previously unreported MAGT1 gene mutations (c.77T>C, p.I26T; c.956-957del: p.Ser319Tyrfs) inherited from their mothers. These mutations expand the spectrum of gene mutations in XMEN disease. The importance of genetic testing for MAGT1 mutations in the initial diagnosis of SETLC was emphasized. We also review the literature on this uncommon IEI.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"356-363"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychosocial Assessment Tool 2.0 and Long-term Mental Health Outcomes in Childhood Cancer. 儿童癌症患者的社会心理评估工具 2.0 和长期心理健康结果。
IF 0.9 4区 医学
Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-08 DOI: 10.1097/MPH.0000000000002935
Cynthia W Karlson, Kimberly G Barajas, Lauren S Erp, Kaysie Winston
{"title":"Psychosocial Assessment Tool 2.0 and Long-term Mental Health Outcomes in Childhood Cancer.","authors":"Cynthia W Karlson, Kimberly G Barajas, Lauren S Erp, Kaysie Winston","doi":"10.1097/MPH.0000000000002935","DOIUrl":"10.1097/MPH.0000000000002935","url":null,"abstract":"<p><p>To identify childhood cancer patients and their families at the greatest risk for psychosocial difficulties, this study examined the predictive validity of the Psychosocial Assessment Tool 2.0 (PAT2.0) on caregiver and patient-reported mental health outcomes at 1-year follow-up. The PAT2.0 was administered to caregivers a median of 0.08 years after cancer diagnosis. A brief psychosocial screening battery (Family Symptom Inventory and PROMIS v1.0 Pediatric Profile-25) was administered to patient-caregiver dyads (n=53) ∼1-year later. Linear regressions support the longitudinal predictive validity of the PAT2.0 for caregiver-reported child and caregiver mental health symptoms and child-reported peer relationships difficulties.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e515-e521"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of BK Virus Infection in Children After Hematopoietic Cell Transplantation: A Retrospective Single-center Study. 造血细胞移植后儿童的 BK 病毒感染分析:单中心回顾性研究
IF 0.9 4区 医学
Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-07-15 DOI: 10.1097/MPH.0000000000002922
Ang Wei, Yuanfang Jing, Guanghua Zhu, Bin Wang, Jun Yang, Chenguang Jia, Yanhui Luo, Yan Yan, Jie Zheng, Xuan Zhou, Maoquan Qin, Tianyou Wang
{"title":"Analysis of BK Virus Infection in Children After Hematopoietic Cell Transplantation: A Retrospective Single-center Study.","authors":"Ang Wei, Yuanfang Jing, Guanghua Zhu, Bin Wang, Jun Yang, Chenguang Jia, Yanhui Luo, Yan Yan, Jie Zheng, Xuan Zhou, Maoquan Qin, Tianyou Wang","doi":"10.1097/MPH.0000000000002922","DOIUrl":"10.1097/MPH.0000000000002922","url":null,"abstract":"<p><strong>Background: </strong>BK virus (BKV) is one of the most common causes of hemorrhagic cystitis (HC) in children undergoing hematopoietic stem cell transplantation (HSCT). Viruses can be found in urine and serum of immunocompromised patients.</p><p><strong>Objective: </strong>This study aimed to evaluate the incidence, clinical course, and risk factors for BKV infection in children undergoing HSCT.</p><p><strong>Methods: </strong>Retrospectively analyzed children who underwent HSCT at Beijing Children's Hospital, Capital Medical University from June 2020 to June 2022. Data related to the clinical manifestations, engraftment, and prognosis were extracted from medical records. Patients were divided into the case group and the control group, according to the BKV infection or not after HSCT.</p><p><strong>Results: </strong>A total of 149 patients were enrolled in this study, and 61 (40.9%) patients developed BKV infection after HSCT. Among the 61 patients, BKV load was detected in all patients in urine samples and 22 patients in blood samples. The median value of BKV DNA copies in urine and plasma were 9.50×10 7 (5.37×10 2 to 6.84×10 9 ) copies/mL and 2.97×10 3 (9.96×10 2 to 3.58×10 8 ) copies/mL, respectively. The median time from beginning of the conditioning regimen to BKV infection was 23 (0 to 273) days, and the first positive time of urinary BKV was earlier than that of blood (13.5 d [0.0 to 123.0 d] vs. 30.5 d [7.0 to 165.0 d], P =0.003). Among the patients with BKV infection, 36 (59.0%) patients met the diagnosis of hemorrhagic cystitis (HC), and the incidence was higher than that in the control group ( P <0.001). Similarly, 15 (24.6%) patients developed renal function damage in the case group and the proportion was higher than that in the control group. The median follow-up was 5.67 (0.03 to 24.90) months, and there was no significant difference in 1-year overall survival rate between the case group and the control group (84.2%±5.7% vs. 95.3%±2.3%, P =0.688), but the incidence of TA-TMA/VOD (31.1%) and diffuse alveolar hemorrhage (9.8%) in the case group was higher than that in the control group ( P =0.002 and 0.038, respectively). Multivariate analysis showed that age above 5 years old (OR=9.039, 95% CI: 3.561-24.333, P <0.001) and use of MMF (OR=2.708, 95% CI: 1.041-7.044, P <0.05) were independent risk factors for BKV infection after HSCT.</p><p><strong>Conclusion: </strong>Among children after HSCT, the incidence of BKV infection was high and BKV infection was associated with an increased incidence of TA-TMA/VOD and diffuse alveolar hemorrhage. Patients older than 5 years of age at the time of HSCT and treated with MMF were more likely to develop BKV infection.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e487-e492"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pyrites: Leukocytosis. 黄铁矿:白细胞增多。
IF 0.9 4区 医学
Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-06-28 DOI: 10.1097/MPH.0000000000002911
Chinith Phauk, Angkeabos Nhip, Sam Lyvannak, Bun Sereyleak, Frank G Keller, Jason Jarzembowski, Bruce Camitta
{"title":"Pyrites: Leukocytosis.","authors":"Chinith Phauk, Angkeabos Nhip, Sam Lyvannak, Bun Sereyleak, Frank G Keller, Jason Jarzembowski, Bruce Camitta","doi":"10.1097/MPH.0000000000002911","DOIUrl":"10.1097/MPH.0000000000002911","url":null,"abstract":"","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"388-389"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141468828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信